Daily Stock Analysis, CUR, Neuralstem Inc, priceseries

Neuralstem Inc. Daily Stock Analysis
Stock Information
Open
0.45
Close
0.47
High
0.49
Low
0.45
Previous Close
0.44
Daily Price Gain
0.03
YTD High
0.49
YTD High Date
Feb 14, 2019
YTD Low
0.25
YTD Low Date
Jan 15, 2019
YTD Price Change
0.14
YTD Gain
42.80%
52 Week High
2.05
52 Week High Date
Apr 10, 2018
52 Week Low
0.25
52 Week Low Date
Jan 15, 2019
52 Week Price Change
-1.06
52 Week Gain
-69.23%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 3. 2017
4.04
Jan 6. 2017
4.36
3 Trading Days
7.72%
Link
LONG
Feb 24. 2017
3.86
Mar 21. 2017
5.42
17 Trading Days
40.46%
Link
LONG
May 31. 2017
4.46
Jun 12. 2017
4.86
8 Trading Days
8.89%
Link
LONG
Jun 21. 2017
5.37
Jul 5. 2017
5.73
9 Trading Days
6.74%
Link
Company Information
Stock Symbol
CUR
Exchange
NasdaqCM
Company URL
http://www.neuralstem.com
Company Phone
301-366-4841
CEO
Richard J. Daly
Headquarters
Maryland
Business Address
20271 GOLDENROD LANE, GERMANTOWN, MD 20876
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001357459
About

Neuralstem, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of central nervous system therapies based on human neuronal stem cells and small molecule compounds. Its patented technology enables the commercial-scale production of central nervous system stem cells. The company was founded by I. Richard Garr, Karl Y. Johe, and Merrill Solomon in 1996 and is headquartered in Germantown, MD.

Description

Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research, development, and commercialization of central nervous system therapies based on its proprietary human neuronal stem cells and stem-cell derived small molecule compounds. The company's stem cell technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its clinical development products include NSI-189, which has completed Phase I clinical trial for the treatment of major depressive disorder, as well as is in Phase I clinical trial for the treatment of other psychiatric and/or cognitive impairment indications associated with hippocampal atrophy; and NSI566 that has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as is in Phase I clinical trials for the treatment of chronic spinal cord injury and motor deficits due to ischemic stroke. The company was founded in 1996 and is headquartered in Germantown, Maryland.